291. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
作者: Gabriel N Hortobagyi.;Salomon M Stemmer.;Howard A Burris.;Yoon-Sim Yap.;Gabe S Sonke.;Shani Paluch-Shimon.;Mario Campone.;Kimberly L Blackwell.;Fabrice André.;Eric P Winer.;Wolfgang Janni.;Sunil Verma.;Pierfranco Conte.;Carlos L Arteaga.;David A Cameron.;Katarina Petrakova.;Lowell L Hart.;Cristian Villanueva.;Arlene Chan.;Erik Jakobsen.;Arnd Nusch.;Olga Burdaeva.;Eva-Maria Grischke.;Emilio Alba.;Erik Wist.;Norbert Marschner.;Anne M Favret.;Denise Yardley.;Thomas Bachelot.;Ling-Ming Tseng.;Sibel Blau.;Fengjuan Xuan.;Farida Souami.;Michelle Miller.;Caroline Germa.;Samit Hirawat.;Joyce O'Shaughnessy.
来源: N Engl J Med. 2016年375卷18期1738-1748页
The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2).
295. Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope.
作者: Paolo Prandoni.;Anthonie W A Lensing.;Martin H Prins.;Maurizio Ciammaichella.;Marica Perlati.;Nicola Mumoli.;Eugenio Bucherini.;Adriana Visonà.;Carlo Bova.;Davide Imberti.;Stefano Campostrini.;Sofia Barbar.; .
来源: N Engl J Med. 2016年375卷16期1524-1531页
The prevalence of pulmonary embolism among patients hospitalized for syncope is not well documented, and current guidelines pay little attention to a diagnostic workup for pulmonary embolism in these patients.
|